FGFR2 and cholangiocarcinoma: Pemigatinib has received approval from by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for treating previously treated, locally advanced, or metastatic CCA with FGFR2 gene rearrangements/fusions based on positive outcomes from the FIGHT-202 trial.